John G. Singer 3/27/25 John G. Singer 3/27/25 Modern Strategy Moves Like a Crab Read More John G. Singer 3/25/25 John G. Singer 3/25/25 Should PhRMA Acquire 23andMe? Read More John G. Singer 3/20/25 John G. Singer 3/20/25 Is Africa a Better 'Vaccine Market' Than the United States? Read More John G. Singer 3/17/25 John G. Singer 3/17/25 Can Novartis Save the NHS? Read More John G. Singer 3/12/25 John G. Singer 3/12/25 What’s the Business Value of the VA to Eli Lilly? Read More John G. Singer 3/5/25 John G. Singer 3/5/25 A Slight Case of Overbombing Read More John G. Singer 3/3/25 John G. Singer 3/3/25 How to Make $164 Billion from “Malaria” — A Modern Strategy Story Read More John G. Singer 2/27/25 John G. Singer 2/27/25 PhRMA Hosts Tiki Barber, Talks Obsolete Game Plan Read More John G. Singer 2/20/25 John G. Singer 2/20/25 Is HIV Prevention and Treatment "Gender-Affirming Care"? Read More John G. Singer 2/17/25 John G. Singer 2/17/25 The Massive Grapple Ahead for Pharma Read More John G. Singer 2/13/25 John G. Singer 2/13/25 How to Sell AI in the Kingdom of the Bored Read More John G. Singer 2/6/25 John G. Singer 2/6/25 Whatever Happened to Eisai’s “Dementia Ecosystem”? Read More John G. Singer 1/31/25 John G. Singer 1/31/25 Should Eli Lilly Acquire Walgreens? Should Novo Nordisk? Read More John G. Singer 1/29/25 John G. Singer 1/29/25 Houston, We Need a New Narrative Read More John G. Singer 1/25/25 John G. Singer 1/25/25 Amazon, LillyDirect and Big Market Innovation Read More John G. Singer 1/16/25 John G. Singer 1/16/25 The Keystone Advantage for Pharma Read More John G. Singer 12/29/24 John G. Singer 12/29/24 The S&P 493 Has Run Out of Ideas Read More John G. Singer 11/27/24 John G. Singer 11/27/24 Understanding the Trump Non-Linearity Read More John G. Singer 11/20/24 John G. Singer 11/20/24 Executive Leaders’ Wile E. Coyote Moment Read More John G. Singer 11/15/24 John G. Singer 11/15/24 Navigating Industry-Level Risk Read More Newer Posts Older Posts
John G. Singer 3/20/25 John G. Singer 3/20/25 Is Africa a Better 'Vaccine Market' Than the United States? Read More
John G. Singer 3/12/25 John G. Singer 3/12/25 What’s the Business Value of the VA to Eli Lilly? Read More
John G. Singer 3/3/25 John G. Singer 3/3/25 How to Make $164 Billion from “Malaria” — A Modern Strategy Story Read More
John G. Singer 2/27/25 John G. Singer 2/27/25 PhRMA Hosts Tiki Barber, Talks Obsolete Game Plan Read More
John G. Singer 2/20/25 John G. Singer 2/20/25 Is HIV Prevention and Treatment "Gender-Affirming Care"? Read More
John G. Singer 2/6/25 John G. Singer 2/6/25 Whatever Happened to Eisai’s “Dementia Ecosystem”? Read More
John G. Singer 1/31/25 John G. Singer 1/31/25 Should Eli Lilly Acquire Walgreens? Should Novo Nordisk? Read More
John G. Singer 1/25/25 John G. Singer 1/25/25 Amazon, LillyDirect and Big Market Innovation Read More
